Modes of inhibition and
An imidazole agent, ketoconazole (cis-1-acety1-4-{4-[[2-(2, 4-dichloropheny1)-2-(1H-imidazol-1-ylmethyl)-1, 3-dioxalan-4-yl] methoxy]phenyll piperazine) is an orally active broad-spectrum antifungal drug. It inhibits production of ergosterol in yeast cell by blocking the14a-demethylation of lanosterol (Van den Bossche et al., 1980) . However, gynecomastia, impotence or adrenal insufficiency has occurred during clinical use of this agent (De Felice et al., 1981; Tucker et al., 1985) , as a result of interference of steroid biosynthesis in both testes and adrenal glands (Pont et al., 1982a, b; Shurmeyer and Nieschlag, 1982) . Steroid synthetic reactions documented to be inhibited by the agent are 17a-hydroxylation and side chain cleavage at C17-20in the rat testis (Sikka et al., 1985) and side chain cleavage of cholesterol and 1113-hydroxylation of deoxycorticosterone in the adrenal gland (Loose et al., 1983; Kowal, 1983) . These reactions are catalyzed by cytochrome HIGASHI et al.
Endocrinol. Japon. February1987 P-450dependent monooxygenases, and in fact, the binding of an imidazole agent, miconazole (1-[2, 4-Dichloro-fid(2, 4-dichlorobenzyl)oxy]phenethyl]imidazole) to cytochrome P-450 component of human placental microsome aromatizing enzyme has been proved by a spectrophotometric study (Mason et al., 1983) .
These data suggest that ketoconazole is a universal inhibitor of cytochrome P-450 dependent monooxygenases which catalyze hydroxylation of many compounds in the process of biosynthesis and catabolism. Up to the present, however, the mechanism of inhibition by ketoconazole has not been well elucidated. Therefore, the present study was designed to clarify the inhibition mode and binding site of ketoconazole to the NADPHcytochrome P-450monooxygenase system using human and rat tissues. cytochrome P-450in rat mitochondrial fraction was obtained as shown in Fig.5 (left   panel) .
In contrast to type I substrateinduced difference spectra of cytochrome P-450in the same tissue preparation with deoxycorticosterone, ketoconazole induced type II spectrum characterized by a peak at432nm and a trough at412nm with zero crossing at423nm (Jefcoate, 1978) (Fig.5, right panel) Comparison of ketoconazole-induced difference spectra of cytochrome P-450in rat and human adrenal glands and rat testes As shown in Fig.6 , cytochrome P-450 in all tissue preparations examined revealed type II spectral change due to the addition of ketoconazole.
Though the difference spectrum of cytochrome P-450in rat testicular microsome was rather obscure, the peak at432nm and the trough at405nm indicated a type II spectrum. We failed to show a binding difference spectrum of rat testicular mitochondrial cytochrome P-450 with ketoconazole. It may be due to the high turbidity and small amount of cytochrome P-450in the testicular preparation.
Substrate-induced difference spectra of cytochrome P-450in rat liver
To investigate whether ketoconazole bound to liver cytochrome P-450in a similar fashion to that mentioned above, spectral binding studies were performed using rat liver microsomal and mitochondrial fractions. As shown in Fig.7 , ketoconazole induced dose-related type II difference spectra to cytochrome P-450in the rat liver. et al., 1985) and rats (Bhasin et al., 1986) , in vitro inhibition of steroidogenesis in cultured mouse adrenal cortex tumor cells (Kowal, 1983) , in vivo inhibition of testosterone production in male rats (Pont et al., 1982b; Trachtenberg, 1984b) and in men (Santen et al., 1983; Schurmeyer and Nieschlag, 1984 Therefore, it appears most likely that ketoconazole is a universal inhibitor of cytochrome P-450dependent monooxygenases. Adverse effects of ketoconazole on liver function can also be attributed at least in part to its inhibitory action on liver cytochrome P-450dependent monooxygenases. One of the reactions catalyzed in vivo by cytochrome P-450dependent monooxygenases plays major roles in activation as well as inactivation of either mutagenic or tumor-promoting agents. Up to the present, however, it is not known whether carcinogenic and tumor-promoting agents might be activated or inactivated in the tissue of humans as a result of the inhibition of cytochrome P-450dependent monooxygenases caused by the administration of ketoconazole. Therefore, great caution should be paid in prolonged administration of ketoconazole as a clinical therapeutic method including antiandrogenic therapy for prostatic cancer, even though recently such clinical trials have been carried out with favorable results (Trachtenberg, 1984a; Heyns et al., 1985) .
